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Background
There is debate about the value of assessing levels of C-reactive protein (CRP) and 
other biomarkers of inflammation for the prediction of first cardiovascular events.
Methods
We analyzed data from 52 prospective studies that included 246,669 participants 
without a history of cardiovascular disease to investigate the value of adding CRP 
or fibrinogen levels to conventional risk factors for the prediction of cardiovascular 
risk. We calculated measures of discrimination and reclassification during follow-
up and modeled the clinical implications of initiation of statin therapy after the 
assessment of CRP or fibrinogen.
Results
The addition of information on high-density lipoprotein cholesterol to a prognostic 
model for cardiovascular disease that included age, sex, smoking status, blood 
pressure, history of diabetes, and total cholesterol level increased the C-index, a 
measure of risk discrimination, by 0.0050. The further addition to this model of 
information on CRP or fibrinogen increased the C-index by 0.0039 and 0.0027, re-
spectively (P<0.001), and yielded a net reclassification improvement of 1.52% and 
0.83%, respectively, for the predicted 10-year risk categories of “low” (<10%), “in-
termediate” (10% to <20%), and “high” (≥20%) (P<0.02 for both comparisons). We 
estimated that among 100,000 adults 40 years of age or older, 15,025 persons would 
initially be classified as being at intermediate risk for a cardiovascular event if conven-
tional risk factors alone were used to calculate risk. Assuming that statin therapy 
would be initiated in accordance with Adult Treatment Panel III guidelines (i.e., for 
persons with a predicted risk of ≥20% and for those with certain other risk factors, 
such as diabetes, irrespective of their 10-year predicted risk), additional targeted 
assessment of CRP or fibrinogen levels in the 13,199 remaining participants at in-
termediate risk could help prevent approximately 30 additional cardiovascular 
events over the course of 10 years.
Conclusions
In a study of people without known cardiovascular disease, we estimated that under 
current treatment guidelines, assessment of the CRP or fibrinogen level in people at 
intermediate risk for a cardiovascular event could help prevent one additional event 
over a period of 10 years for every 400 to 500 people screened. (Funded by the British 
Heart Foundation and others.)
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There is an evolving debate about the value of assessing levels of C-reactive protein (CRP) and other soluble biomark-
ers of inflammation for the prediction of first 
cardiovascular events. In 2003, the Centers for 
Disease Control and Prevention and the American 
Heart Association (AHA) concluded that CRP may 
be used at the discretion of a physician as part of 
a global assessment of cardiovascular risk.1 In 2007, 
the European Society of Cardiology described as 
“premature” the incorporation of CRP assessment 
into standard models for the prediction of cardio-
vascular risk.2 In 2009, the Canadian Cardiovas-
cular Society recommended CRP assessment in 
patients at “intermediate risk,” which was defined 
as the predicted risk of a cardiovascular event over 
the subsequent 10 years of 10% to less than 20%.3 
Also in 2009, the National Academy of Clinical 
Biochemistry Laboratory Medicine Practice Guide-
lines concluded that measurement of CRP levels 
might be useful in the stratification of patients at 
intermediate risk for a cardiovascular event, al-
though the evidence for the usefulness of mea-
sures of fibrinogen and other biomarkers of in-
flammation was considered to be inconclusive.4 
A report by the American College of Cardiology 
Foundation–AHA Task Force on Practice Guide-
lines in 2010 stated that assessment of CRP levels 
is reasonable for patients at intermediate risk.5 It 
is expected that further guidelines regarding these 
biomarkers will emerge, such as the updated 
guidelines on cholesterol (Adult Treatment Panel 
[ATP] IV) that are part of the integrated set of 
guidelines on cardiovascular risk reduction from 
the National Heart, Lung, and Blood Institute.6
We analyzed individual records of 246,669 
people without a history of cardiovascular disease 
at baseline from 52 prospective cohort studies. 
Our aim was to quantify the improvement in the 
prediction of a first cardiovascular event when the 
assessment of circulating biomarkers of inflam-
mation was added to the assessment of risk factors 
used in standard risk scores. Our principal focus 
was CRP and fibrinogen levels and our secondary 
focus was leukocyte count and albumin level — 
all of which are acute-phase reactants.
Me thods
Study Oversight
Details of the Emerging Risk Factors Collabora-
tion have been described previously.7 The current 
study was designed and conducted by the indepen-
dent coordinating center of the collaboration and 
was approved by the ethics review committee in 
Cambridgeshire, United Kingdom. The first three 
members and the last member of the writing com-
mittee vouch for the accuracy of the data and anal-
yses and submitted the article for publication. 
GlaxoSmithKline, which provided an unrestricted 
educational grant to the coordinating center, 
played no role in the collection, analysis, or re-
porting of the data.
Study Cohorts
Prospective cohort studies were included in the 
current analysis if they met all the following cri-
teria: participants who did not have a recorded 
baseline history of cardiovascular disease (i.e., 
myocardial infarction, angina, or stroke, which 
were defined in each study at the initial examina-
tion) were included; cause-specific deaths or vas-
cular events (nonfatal myocardial infarction or 
stroke) or both, as assessed according to well-
defined criteria, were recorded during follow-up; 
and data were recorded for more than 1 year of 
follow-up. In addition, studies were included only 
if data on baseline levels of CRP, fibrinogen, or 
both had been obtained and if complete informa-
tion on age, sex, smoking status, history of diabe-
tes, systolic blood pressure, and levels of total and 
high-density lipoprotein (HDL) cholesterol (i.e., 
“conventional risk factors” included in standard 
clinical risk scores8) had been collected.
Some data used in the reported analyses were 
available only in a subset of study participants. 
These included data on leukocyte count, levels of 
albumin and directly measured low-density lipo-
protein (LDL) cholesterol, socioeconomic factors, 
and family history of cardiovascular disease. In 
registering fatal outcomes, all contributing studies 
used International Classification of Disease, revisions 
8, 9, and 10, coding to at least three digits, and 
ascertainment was based on death certificates, 
with 46 studies also using medical records, au-
topsy findings, and other supplementary sources. 
All the studies used a definition of myocardial 
infarction that was based on World Health Orga-
nization (or similar) criteria and a definition of 
stroke that was based on the results of clinical 
examination and findings on brain imaging.
Statistical Analysis
For all analyses, values for CRP and leukocyte 
count were loge-transformed. The main outcome 
was a first cardiovascular event, defined as a myo-
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cardial infarction or fatal coronary heart disease 
or any stroke. Cox proportional-hazards modeling 
allowed for the determination of separate baseline 
hazards according to study and sex, but common 
coefficients (log hazard ratios) were estimated 
across studies (see the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org). We censored outcomes for patients who died 
from noncardiovascular causes. The proportional-
hazards assumption was satisfied.
Prognostic models were compared with the use 
of measures of discrimination (i.e., the C-index 
and the D measure, both of which quantify the 
degree to which a model can predict the order of 
disease events)9 and risk reclassification10 (see the 
Supplementary Appendix). We extended our pre-
vious methods9 to include a two-stage approach 
that allowed for the examination of between-
study heterogeneity through calculation of the 
C-index, the D measure, and changes therein 
within each individual study before pooling re-
sults. Studies were weighted according to the 
numbers of cardiovascular outcomes contributed. 
Between-study heterogeneity in the risk-discrim-
ination measures and their changes was quanti-
fied with the use of the I2 statistic.11 We used 
chi-square tests to determine differences in chang-
es in discrimination measures across subgroups. 
We constructed reclassification tables with data 
from studies in which both fatal and nonfatal 
cardiovascular outcomes had been recorded to 
examine the movement of participants among 
three predicted 10-year cardiovascular risk cate-
gories (“low,” <10%; “intermediate,” 10% to <20%; 
and “high,” ≥20%) when CRP or fibrinogen val-
ues were added to a model that included conven-
tional risk factors.5 For clinical modeling, we 
assumed that statin treatment reduces cardiovas-
cular risk by 20%.12-14 Analyses were performed 
with the use of Stata software, version 11.0. All 
P values are two-sided.
R esult s
Characteristics of the Study participants
A total of 52 studies involving 246,669 partici-
pants were included in the analysis. Overall, the 
mean (±SD) age at baseline was 61±9 years. In 
aggregate, 56% of the participants were men; 
57% were from Western Europe, and 34% were 
from North America. Information on CRP levels 
was available for 166,596 participants from 38 pro-
spective cohorts (Table S1 in the Supplementary 
Appendix), among whom there were 13,568 first 
cardiovascular events (8816 coronary heart disease 
events and 4752 strokes) during 1.6 million person-
years at risk (median number of years to first out-
come, 6.7). Information on fibrinogen levels was 
available for 185,892 participants from 40 cohorts 
(Table S2 in the Supplementary Appendix), among 
whom there were 12,021 first cardiovascular 
events (7475 coronary heart disease events and 
4546 strokes) during 1.7 million person-years at 
risk (median number of years to first outcome, 
5.9). Information on both CRP and fibrinogen lev-
els was available for 95,733 participants. Table 1 
shows the baseline characteristics of participants 
who were included in the CRP and fibrinogen anal-
yses, as well as adjusted hazard ratios for first car-
diovascular events.
Incremental Value in Risk Prediction
The addition of HDL cholesterol to a prognostic 
model for first cardiovascular events that included 
data on age, sex, smoking status, blood pressure, 
history of diabetes, and total cholesterol increased 
the C-index by 0.0050 (Fig. 1, and Table S3 in the 
Supplementary Appendix). The further addition of 
information on a biomarker of inflammation to 
this model increased the C-index by 0.0039 with 
CRP levels and by 0.0027 with fibrinogen levels 
(Fig. 1, and Table S4 and Fig. S1 and S2 in the 
Supplementary Appendix), yielding a net reclas-
sification improvement of 1.52% and 0.83%, re-
spectively, for the predicted 10-year risk catego-
ries of low (<10%), intermediate (10% to <20%), 
and high (≥20%) (P<0.02 for both comparisons) 
(Tables S5 and S6 in the Supplementary Appen-
dix). The corresponding values for the integrated 
discrimination index were 0.0036 and 0.0027.
In analyses that limited the outcome to coro-
nary heart disease, the combined predictive value 
of total and HDL cholesterol was greater than that 
of either CRP or fibrinogen (Fig. 1). In contrast, in 
analyses of stroke, neither the biomarkers of 
inflammation nor the measures of cholesterol 
increased the C-index substantially over the 
C-index for the model that did not include mea-
sures of lipids.
In analyses limited to participants with data 
on both CRP and fibrinogen, the change in the 
C-index when both markers were used was broad-
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ly similar to the change when either marker was 
used alone (Table 2). The effects of adding infor-
mation on CRP or fibrinogen were similar in 
analyses that included measures of body-mass 
index, family history of cardiovascular disease, 
or both as risk factors in the standard prediction 
model (Table S7 in the Supplementary Appen-
dix); in analyses that omitted extreme CRP or 
fibrinogen values; and in analyses that omitted 
participants known to be taking medications at 
study entry that lowered lipid levels or blood pres-
sure (Fig. S3 in the Supplementary Appendix). 
Total cholesterol levels were also similarly effec-
tive in predicting cardiovascular events in par-
ticipants known to be taking statins and in those 
not taking statins (P = 0.74 for the interaction).
Improvements observed in the C-index when 
leukocyte count or albumin level was added to 
the analysis did not differ significantly from those 
observed with the addition of CRP or fibrinogen 
(Table 2), although concomitant information on 
CRP, fibrinogen, and at least one other biomarker 
of inflammation was available for only about one 
third of the participants. Results qualitatively 
similar to those described above were observed 
in analyses that used the D measure (Table S8 in 
the Supplementary Appendix). In analyses in which 
one risk factor at a time was omitted from a 
model containing conventional risk factors plus 
measures of CRP or fibrinogen, the results when 
values for CRP or fibrinogen were omitted were 
broadly similar to those when values for total or 
HDL cholesterol were omitted (Fig. S4 in the 
Supplementary Appendix).
Effect of Assessment in Clinically Relevant 
Subgroups
The use of information on CRP and fibrinogen 
improved cardiovascular risk discrimination in 
men but not in women (P≤0.001 for the interac-
tion). CRP also had greater predictive value in cur-
rent smokers than in nonsmokers (P<0.001 for 
the interaction) (Fig. 2). There were no signifi-
cant differences in cardiovascular risk discrimi-
nation in other clinically relevant subgroups (Fig. 
2, and Fig. S3 in the Supplementary Appendix). 
The differences in the improvement of cardiovas-
cular risk discrimination according to sex with 
the use of information on CRP and fibrinogen 
levels persisted in further analyses in which par-
ticipants were stratified according to smoking 
status (or in which smokers were omitted) and in 
analyses in which women who were known to be 
receiving hormonal treatment at baseline were ex-
Table 1. Baseline Characteristics and Hazard Ratios for First-Onset Cardiovascular Disease.*
Characteristic
Participants with Assessment 
of C-Reactive Protein
(N = 166,596)
Hazard Ratio 
(95% CI)†
Participants with Assessment 
of Fibrinogen
(N = 185,892)
Hazard Ratio 
(95% CI)†
Mean age at time of survey — yr 59.7±8.6 1.90 (1.86–1.94) 59.3±8.4 1.81 (1.77–1.85)
Male sex — no. (%) 82,077 (49) NA‡ 100,530 (54) NA‡
Current smoker — no. (%) 35,779 (21) 1.64 (1.58–1.71) 46,799 (25) 1.71 (1.64–1.78)
Systolic blood pressure — mm Hg 136±19 1.26 (1.24–1.28) 137±18 1.30 (1.28–1.32)
History of diabetes — no. (%) 10,802 (6) 1.74 (1.64–1.85) 11,287 (6) 1.89 (1.79–2.00)
Total cholesterol — mmol/liter 5.86±1.06 1.17 (1.15–1.19) 5.80±1.08 1.19 (1.17–1.21)
HDL cholesterol — mmol/liter 1.32±0.38 0.86 (0.84–0.88) 1.32±0.39 0.85 (0.83–0.87)
Loge CRP — mg/liter 0.59±1.09 1.20 (1.18–1.22) — —
Fibrinogen — g/liter — — 3.15±0.74 1.15 (1.13–1.17)
* Plus–minus values are means ±SD. Data on C-reactive protein are from 38 studies in which 13,568 participants had a first-ever cardiovascu-
lar disease outcome during follow-up, and data on fibrinogen are from 40 studies in which 12,021 participants had a first-ever cardiovascu-
lar disease outcome during follow-up. Dashes indicate that summary statistics are not applicable for either CRP or fibrinogen because the 
models used were based on two separate sets of data to maximize the information on each marker. CRP denotes C-reactive protein.
† The hazard ratios were calculated per 1-SD increment in the measured level or as compared with the relevant reference category. Where ap-
propriate, hazard ratios were adjusted for age, sex, smoking status, systolic blood pressure, diabetes status, and levels of total cholesterol, 
high-density lipoprotein (HDL) cholesterol, and C-reactive protein or fibrinogen.
‡ Hazard ratios according to sex are not available (NA) because these models were stratified by sex.
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cluded, although information on such treatments 
was incomplete.
To further explore sex-specific findings, we 
assessed reclassification using data only from 
15 studies that involved both men and women 
with at least 10 years of follow-up (19,467 men 
with 2784 first cardiovascular events and 25,157 
women with 2323 first cardiovascular events). In 
these studies, the net improvement in reclassifi-
cation with measurement of CRP among men was 
1.24% (95% confidence interval [CI], −0.20 to 2.69; 
P = 0.09), and the net improvement among wom-
en was 0.36% (95% CI, −0.70 to 1.42; P = 0.51). The 
effect modification according to sex was not ob-
served with measures of HDL cholesterol or sys-
tolic blood pressure (Fig. S5 in the Supplementary 
Appendix). Similarly, there was no evidence of ef-
fect modification according to age when analyses 
of CRP or fibrinogen were conducted only with 
data from studies that included participants in 
each of three age groups (40 to <60 years, 60 to 
<70 years, and ≥70 years; P = 0.62) (Fig. S6 in the 
Supplementary Appendix).
Estimate of the Potential for Disease 
Prevention
We modeled targeted CRP or fibrinogen assess-
ment in people whose risk of a cardiovascular 
event was 10% to less than 20% over the subse-
quent 10 years. In a population of 100,000 adults 
40 years of age or older, with an age profile sim-
ilar to that in the European standard population 
and with age-specific and sex-specific incidences 
of cardiovascular events that are assumed to be 
the same as those observed in the current study 
(see the Supplementary Appendix), 15,025 persons 
would initially be classified as having a predicted 
risk of cardiovascular disease of 10% to less than 
20% over a period of 10 years when the risk is 
calculated with conventional risk factors alone 
(Fig. 3). Assuming that allocation to statin treat-
ment would be conducted according to the ATP-
III guidelines15 (i.e., persons with a predicted risk 
of ≥20% and those with risk factors, such as dia-
betes, irrespective of their predicted 10-year risk), 
13,199 participants at intermediate risk would cur-
rently not be eligible for statin treatment. Addition-
Table 2. Changes in the C-Index after the Addition of Information on Biomarkers of Inflammation to a Model Including Conventional Risk 
Factors.*
Data Source and Risk Factor
Change in C-Index after 
Addition of Biomarker 
(95% CI)
P Value for Comparison 
with Model Including  
Conventional Risk Factors
P Value for 
Comparison 
with Reference
25 Studies with 95,733 participants, 6609 with CVD
Conventional risk factors plus loge CRP 0.0035 (0.0018–0.0051) <0.001 Reference
Conventional risk factors plus fibrinogen 0.0022 (0.0010–0.0035) <0.001 0.13
Conventional risk factors plus loge CRP and fibrinogen 0.0040 (0.0023–0.0057) <0.001 0.10†
10 Studies with 32,160 participants, 3498 with CVD
Conventional risk factors plus loge CRP 0.0031 (0.0010–0.0053) 0.004 Reference
Conventional risk factors plus loge leukocyte count 0.0028 (0.0011–0.0045) 0.002 0.78
17 Studies with 61,002 participants, 8646 with CVD
Conventional risk factors plus loge CRP 0.0038 (0.0023–0.0053) <0.001 Reference
Conventional risk factors plus albumin 0.0022 (0.0014–0.0030) <0.001 0.05
15 Studies with 46,699 participants, 5227 with CVD
Conventional risk factors plus fibrinogen 0.0037 (0.0020–0.0053) <0.001 Reference
Conventional risk factors plus loge leukocyte count 0.0036 (0.0022–0.0051) <0.001 0.97
16 Studies with 62,502 participants, 6476 with CVD
Conventional risk factors plus fibrinogen 0.0034 (0.0020–0.0048) <0.001 Reference
Conventional risk factors plus albumin 0.0032 (0.0019–0.0044) <0.001 0.79
* Conventional risk factors include age, systolic blood pressure, smoking status, diabetes status, and levels of total and HDL cholesterol. 
“Reference” refers to the comparator model. CRP denotes C-reactive protein, and CVD cardiovascular disease.
† P = 0.003 for the comparison of the addition of loge CRP to a model with fibrinogen.
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al assessment of CRP in these 13,199 participants 
would reclassify 690 participants (5.2%) to a pre-
dicted risk of 20% or more, of whom approximate-
ly 151 would be expected to have a cardiovascular 
event within 10 years; correspondingly, additional 
assessment of fibrinogen in the same participants 
would reclassify 625 (4.7%) to a predicted risk of 
20% or more, of whom approximately 134 would 
be expected to have a cardiovascular event within 
10 years. Assuming that persons reclassified as 
0.000 0.005 0.010 0.015 0.020
C-Index Change (95% CI), with Addition
of Loge CRP
Overall
 Sex
Male
Female
Smoking status
Not current
Current
History of diabetes
No
Yes
Predicted 10-yr CVD risk
<10%
10% to <20%
≥20%
13,568
5,755
4,535
8,880
4,688
11,418
1,580
1,602
3,903
7,417
−0.005
C-Index Change
(95% CI)
P Value for
HeterogeneitySubgroup
CVD
Cases
0.0039 (0.0028 to 0.0050)  
0.0077 (0.0058 to 0.0096)  
0.0007 (−0.0007 to 0.0021)
0.0027 (0.0015 to 0.0039)  
0.0089 (0.0064 to 0.0115)  
0.0042 (0.0029 to 0.0055)  
0.0026 (−0.0015 to 0.0067)
0.0029 (−0.0023 to 0.0081)
0.0116 (0.0065 to 0.0166)  
0.0095 (0.0070 to 0.0121)  
NA
<0.001
<0.001
0.48
0.04
0.000 0.005 0.010 0.015 0.020
C-Index Change (95% CI), with Addition
of Fibrinogen
Overall
 Sex
Male
Female
Smoking status
Not current
Current
History of diabetes
No
Yes
Predicted 10-yr CVD risk
<10%
10% to <20%
≥20%
12,021
4,438
3,368
7,819
4,202
10,142
1,868
1,509
3,301
6,233
−0.005
C-Index Change
(95% CI)
P Value for
HeterogeneitySubgroup
CVD
Cases
0.0027 (0.0018 to 0.0036)  
0.0043 (0.0029 to 0.0057)  
0.0011 (−0.0004 to 0.0025)
0.0024 (0.0013 to 0.0036)  
0.0041 (0.0021 to 0.0061)  
0.0026 (0.0015 to 0.0037)  
0.0037 (0.0007 to 0.0068)  
0.0015 (−0.0034 to 0.0064)
0.0094 (0.0045 to 0.0144)  
0.0068 (0.0044 to 0.0093)  
NA
0.001
0.15  
0.50  
0.07  
A C-Reactive Protein
B Fibrinogen
Figure 2. Changes in the C-Index with the Addition of Information on C-Reactive Protein or Fibrinogen to a Model 
with Conventional Risk Factors, According to Subgroup.
P values are for differences in the C-index changes across subgroups. Error bars indicate 95% confidence intervals. 
For each comparison, only studies with information on all subgroup levels were used (hence, subgroup total num-
bers do not always equal overall total numbers). Since not all the contributing studies had complete information 
across all subgroup levels, comparisons across subgroups (e.g., men vs. smokers) may not be reliable owing to be-
tween-study differences. “Predicted 10-year CVD risk” refers to the predicted 10-year risk of cardiovascular disease 
events calculated on the basis of the 2008 version of the Framingham risk score.
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being at a predicted risk of 20% or more would 
begin statin therapy, in accordance with the ATP-
III criteria, such targeted assessment of CRP could 
help to prevent about 30 (i.e., 0.20 × 151) additional 
cardiovascular events over a period of 10 years; the 
corresponding assessment of fibrinogen could help 
to prevent about 27 (i.e., 0.20 × 134) additional car-
diovascular events over a 10-year period.
In other words, targeted assessment of CRP in 
people at intermediate risk for a cardiovascular 
event could help to prevent one additional event 
over the course of 10 years for every 440 people so 
screened (i.e., 13,199 ÷ 30), as a result of about 
23 additional people starting statin therapy (i.e., 
5.2% × 440). The corresponding number needed to 
screen with targeted fibrinogen assessment would 
be about 490 (i.e., 13,199 ÷ 27). Alternatively, as-
suming that only people with a predicted risk of 
20% or more were started on statin therapy, as 
recommended in Canadian3 and U.K.16 guidelines, 
the assessment of CRP could help prevent one extra 
cardiovascular event for approximately 360 people 
at intermediate risk so screened (Fig. S7 in the 
Supplementary Appendix). If subsequent analyses 
confirm that such improvements are limited to 
men, one extra cardiovascular event could be pre-
vented for approximately every 390 men at interme-
diate risk in whom CRP levels were assessed (the 
corresponding number for targeting women would 
be one event prevented for every 740 women with 
CRP assessment).
Discussion
In an analysis comprising individual participant 
data from 52 prospective cohort studies, we eval-
uated the effects of adding information on CRP 
or fibrinogen to the standard risk factors used to 
predict the risk of a first cardiovascular event. We 
then modeled a scenario in which CRP or fibrin-
ogen was assessed in people considered to be at 
intermediate risk (a predicted risk of 10% to 
<20% over a period of 10 years) after initial 
screening with the use of conventional risk factors 
alone. If such measurement of a biomarker of 
inflammation were to be coupled with initiation 
of statin therapy in accordance with the recom-
mendations of the ATP-III guidelines,15 our data 
suggest that one extra cardiovascular disease out-
come would be prevented over a period of 10 years 
for approximately every 440 people in whom 
Stratification of 10-yr CVD risk, according
to conventional risk factors
Per 100,000 screened
76,945 Are at <10% risk
for CVD
2,758 Cases
74,187 Noncases
8,030 Are at ≥20% risk
for CVD
2,510 Cases
5,520 Noncases
Assumed to be at
low risk
Treatment assumed
15,025 Are at 10 to <20%
risk for CVD
2,083 Cases
12,942 Noncases
13,199 Are at 10 to <20% risk for CVD
1,738 Cases
11,461 Noncases
Treatment assumed per
ATP-III guidelines
Reclassification of 10-yr CVD risk with
additional CRP or fibrinogen screening 
Fibrinogen screeningCRP screening
1,522 Are at <10% risk for CVD
130 Cases
1,392 Noncases
10,987 Are at 10 to <20% risk 
for CVD
1,457 Cases
9,530 Noncases
690 Are at ≥20% risk for CVD
151 Cases
539 Noncases
1,108 Are at <10% risk for CVD
91 Cases
1,017 Noncases
11,466 Are at 10 to <20% risk 
for CVD
1,513 Cases
9,953 Noncases
625 Are at ≥20% risk for CVD
134 Cases
491 Noncases
Figure 3. Modeling of Reclassification per 100,000 Persons Initially Screened 
for Conventional Risk Factors Only and Then Screened for C-Reactive Protein 
or Fibrinogen.
Reclassification was based on observed data from participants with complete 
information on conventional risk factors and CRP levels (72,574 participants 
in 22 studies) or fibrinogen levels (83,061 participants in 27 studies). Adult 
Treatment Panel (ATP) III guidelines recommend treatment in only 1826 of 
these people (e.g., persons with diabetes) in the intermediate risk group, 
leaving 13,199 people in this group currently ineligible for treatment with 
statins. Details of the modeling are available in the Supplementary Appendix. 
CVD denotes cardiovascular disease.
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CRP levels were assessed or approximately every 
490 people in whom fibrinogen levels were as-
sessed, as a result of the initiation of statin ther-
apy in about 23 additional people. Analyses in 
which both CRP and fibrinogen levels were in-
cluded showed results that were broadly similar to 
those in which either biomarker alone was used.
Our main model assumed that the assessment 
of CRP or fibrinogen would provide similar pre-
dictions of the risk of cardiovascular events across 
population subgroups. However, a finding from an 
exploratory analysis suggested that these biomark-
ers improve risk discrimination only in men. This 
result could, at least to some extent, be due to the 
play of chance, since we studied the interaction of 
CRP and fibrinogen with a number of factors, and 
there is currently no good explanation for the find-
ing. We therefore believe that this finding requires 
cautious interpretation. Nevertheless, if this find-
ing were confirmed in subsequent analyses, tar-
geting the assessment of CRP or fibrinogen only in 
men at intermediate risk should enhance screen-
ing efficiency.
Recently developed risk prediction scores have 
tended to combine the outcomes of coronary heart 
disease and stroke because these outcomes have 
similar risk factors and treatments; therefore, the 
primary outcome of our study was any first cardio-
vascular event (defined as fatal or nonfatal coro-
nary heart disease or stroke). However, some risk 
scores relate solely to coronary heart disease17 and 
others relate solely to stroke.18 Our results con-
firm that the relative usefulness of risk factors in 
prediction can vary considerably depending on 
whether the outcome chosen includes all cardio-
vascular events or coronary heart disease events 
only. Furthermore, risk scores proposed solely for 
the prediction of stroke may involve additional risk 
factors that are not considered here, such as atrial 
fibrillation.18
The strengths and potential limitations of this 
study merit consideration. Our analysis involved 
populations from 16 countries. We found broadly 
concordant results among several measures of risk 
reclassification and discrimination. Although we 
used a conventional 10-year time frame and stan-
dard clinical risk categories, we acknowledge that 
such reclassification analyses are sensitive to the 
choices of landmark time and risk categories. We 
found that the differences among studies in levels 
of biomarkers of inflammation contributed rela-
tively little to the heterogeneity in our results, 
which was due mostly to differing age ranges 
across cohorts. We had incomplete information on 
statin use, which may have influenced our esti-
mates of the effect of individual risk factors or risk 
models on outcomes. Our models could have over-
estimated the potential benefits of statins because 
we assumed that all eligible people would receive 
them. Conversely, somewhat greater clinical effect 
than that estimated here would be projected if we 
had used less conservative modeling assumptions, 
such as more efficacious statin regimens,12,19 or 
longer time horizons, such as those in lifetime risk 
estimates. However, the findings from this study 
should aid in the modeling of such scenarios.
Several other issues warrant further investiga-
tion. The measurement of biomarkers of inflam-
mation should be compared with the use of other 
emerging biomarkers (including imaging biomark-
ers)4,5,20-23 with regard to cost-effectiveness,24,25 
practicability, and clinical benefit.26 Because pro-
spective associations have previously been ob-
served between the biomarkers studied here and 
the risk of several major nonvascular diseases as 
well as cardiovascular disease,27-29 further study is 
needed to determine the value of these biomark-
ers in screening concurrently for various chronic 
diseases.30
In conclusion, we analyzed individual records 
from 52 cohort studies to investigate the value of 
adding information on CRP or fibrinogen levels to 
conventional models for the prediction of cardio-
vascular risk among people without known car-
diovascular disease. We estimated that under cur-
rent treatment guidelines, after initial screening 
with conventional risk factors alone, the additional 
assessment of CRP or fibrinogen in people at in-
termediate risk for a cardiovascular event could 
help prevent one additional event over a period of 
10 years for every 400 to 500 people so screened.
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